Search
Simcere Pharmaceutical, in partnership with Idorsia, has secured marketing approval from the National Medical Products Administration (NMPA) for its groundbreaking anti-insomnia medication, Quviviq® (Daridorexant Hydrochloride Tablets). This drug is specifically designed for adult patients who struggle with initiating and/or maintaining sleep, and it is not categorized as a controlled psychotropic substance. The pivotal Phase III clinical trial in China was spearheaded by Professor Wang Yuping from Xuanwu Hospital, Capital Medical University. The findings revealed that Quviviq® significantly improved sleep onset time, sleep quality, and daytime functionality, while demonstrating favorable safety and tolerability profiles. The company anticipates that Quviviq® will be available for commercial purchase by the end of this year.
-
C114 Communication Network -
Communication Home
